NVTR - Axonics Modulation Seeks $86 Million In U.S. IPO
Quick Take
Axonics Modulation Technologies (AXNX) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm develops and commercializes minimally invasive sacral neuromodulation (SNM) solutions.
AXNX hopes to raise public capital to finalize its U.S. regulatory efforts and begin commercialization of its SNM device.
Company & Technology
Irvine, California-based Axonics Modulation was founded in 2013 to develop and market a minimally invasive rechargeable SNM (r-SNM) system for patients with overactive bladder [OAB], fecal incontinence [FI], and urinary retention [UR].
Management is headed